Drug Company Mylan Understated its Profit Margin on EpiPen

According to Sources close to the matter, the drug company Mylan said on Monday the auto-injector EpiPen’s pretax profits were 60 percent higher than it told Congress. Without a tax-related reduction, the pharmaceutical company’s profits on the EpiPen two-pack would be about $160, higher than the $100 figure the company gave Congress. The company said any lack of clarity was not intentional.

In a statement, Mylan said the following:

“Tax is typically included in a standard profitability analysis and the information provided to Congress has made clear that tax was part of the EpiPen Auto-Injector profitability analysis. In fact, Mylan has provided Congress with a detailed analysis of EpiPen Auto-Injector profitability.”

The company added:

“It also is important to note that use of a statutory tax rate for the jurisdiction being analyzed (in this instance, the U.S.) is standard. Just as we did not use a blended global tax rate, we also did not allocate corporate expenses associated with running the business, which would have further reduced its profitability. We believe it is most appropriate, and conservative, to focus entirely on EpiPen Auto-Injector specific costs and associated taxes.”

The company has found itself under scrutiny since people started seeing the cost of EpiPen rise to unaffordable costs. To such ends that people believe it is unethical to charge so much for a drug that without it, will result in people with severe allergies dying as a result.

Last week, Mylan CEO Heather Bresch testified before a congressional committee about steep price increases on the lifesaving anti-allergic-reaction drug. House members asked Bresch to provide more evidence for the company’s claim that its profits were just $100 for a two-pack of the injectors, despite a $608 list price, according to Dow Jones.

It may strike some as very convenient that the math was done wrong in a way that makes the drug seem a little more affordable despite people saying otherwise. Possibly the drug company who denies doing so, presented the false numbers in hopes the mistake would not be discovered but with the plan that if it were discovered they simply say as they are now it was a mistake. Quite sure a mistake such as this would not be made with the numbers on the sales shelf, that is with the price.

About Zachary Dahl

AvatarHello and good day. My name is Zachary Dahl. Currently I live and work in New York City. I really enjoy going out to eat here and the diversity of foods available to me. I also enjoy the arts and culture the city affords me with countless museums, art shows and neighborhoods.
In my downtime I really enjoy spending time in my small herb garden which has grown beyond my expectations. Its so nice to just sit out there after the stresses of the day and unwind.
Lastly I really enjoy the art that is writing. I feel it can transport you to anywhere you desire and is one of my most treasured tools. Like most writers I have ambitions to publish, but am proud and happier than you could know at embarking on this internship.

Have a tip we should know? tips@rhd.news


Most Read

  1. Politics
    Jamal Khashoggi: US Defends Not Sanctioning MBS For Murder
    5 mins ago
  2. WORLD
    Iran Rules Out talks With US, EU To Discuss Nuclear Deal Revival
    21 hours ago
  3. Asia Pacific
    Myanmar coup: Deadliest Day Of Protests As Police Open Fire
    22 hours ago
  4. U.S.
    Trump Rules Out New Political Party In Speech To Conservatives
    22 hours ago
  5. Middle East
    Syria Says Israel Attacked Areas Around Southern Damascus
    1 day ago
    Storm Ventures promotes Pascale Diaine and Frederik Groce to Partners
    1 day ago
    Celebrity Video Platform Memmo banks $10 million
    2 days ago

Follow @rushhourdaily: